P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome
International Journal of Molecular Sciences · 14.05.2025 · 26 (10) · 4701
DOI: 10.3390/ijms26104701 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.05.2025. Verfasst von Pablo Álvarez-Carrasco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Antineoplastic Agents, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dirección General de Políticas de Investigación en Salud, Hospital Infantil de México Federico Gómez.
Abstract (Originalsprache)
P-glycoprotein (P-gp), a transmembrane efflux pump encoded by the ABCB1/MDR1 gene, is a major contributor to multidrug resistance in hematological malignancies. These malignancies, arising from hematopoietic precursors at various differentiation stages, can manifest in the bone marrow, circulate in the bloodstream, or infiltrate tissues. P-gp overexpression in malignant cells reduces the efficacy of chemotherapeutic agents by actively expelling them, decreasing intracellular drug concentrations, and promoting multidrug resistance, a significant obstacle to successful treatment. This review examines recent advances in combating P-gp-mediated resistance, including the development of novel P-gp inhibitors, innovative drug delivery systems (e.g., nanoparticle-based delivery), and strategies to modulate P-gp expression or activity. These modulation strategies encompass targeting relevant signaling pathways (e.g., NF-κB, PI3K/Akt) and exploring drug repurposing. While progress has been made, overcoming P-gp-mediated resistance remains crucial for improving patient outcomes. Future research directions should prioritize the development of potent, selective, and safe P-gp inhibitors with minimal off-target effects, alongside exploring synergistic combination therapies with existing chemotherapeutics or novel agents to effectively circumvent multidrug resistance in hematological malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico.
- Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- Facultad de Medicina, Benemérita Universidad de Puebla, Puebla 72000, Mexico.
ORCID-Profile: Carmen Maldonado-Bernal
Förderung
- Dirección General de Políticas de Investigación en Salud
- Hospital Infantil de México Federico Gómez
Zitieren
APA
Álvarez-Carrasco, P., Morales-Villamil, F., & Maldonado-Bernal, C. (2025). P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome. International Journal of Molecular Sciences, 26(10), 4701. https://doi.org/10.3390/ijms26104701
Vancouver
Álvarez-Carrasco P, Morales-Villamil F, Maldonado-Bernal C. P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome. International Journal of Molecular Sciences. 2025;26(10):4701. doi:10.3390/ijms26104701
BibTeX
@article{lvarezCarrasco2025,
author = {Álvarez-Carrasco, Pablo and Morales-Villamil, Fernanda and Maldonado-Bernal, Carmen},
title = {P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {10},
pages = {4701},
doi = {10.3390/ijms26104701}
}
EUVIMED